Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2019
(WorldNews Norway)

Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2019 Nordic Nanovector ASA (OSE: NANO) announces its results for the fourth quarter and full year 2019. A presentation by the company`s senior management team will take place today in Oslo at 08:30 CET, see details below. Jan H. Egberts, MD, Chairman of Nordic Nanovector, commented: `We currently have 47 patients enrolled in our pivotal PARADIGME Phase 2b trial evaluating Betalutin®. The company will under its new management look into the current strategy and operational trial initiatives. We still aim to complete the patient enrolment in PARADIGME in the second half of 2020. The encouraging efficacy and safety profile...